Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma

Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma

(2009) K. Dunleavy et al.   BLOOD

Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre phase 2 clinical trial

(2009) Owen A. O’Connor et al.   BRITISH JOURNAL OF HAEMATOLOGY

Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma

(2009) Vincent Ribrag et al.   CANCER

Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma

(2008) J. Lee et al.   ANNALS OF ONCOLOGY

Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study

(2008) A. Goy et al.   ANNALS OF ONCOLOGY

Stromal Gene Signatures in Large-B-Cell Lymphomas

(2008) G. Lenz et al.   NEW ENGLAND JOURNAL OF MEDICINE